Clinical trial
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
NCT02275117 is registered in ClinicalTrials.gov with Alder Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- November 30, 2016
- Enrollment
- 665 (actual)
- Sites
- 92
Conditions
As the registry lists them; a condition with its own page is linked.